PicoCELA (NASDAQ:PCLA) Upgraded to “Hold” at Wall Street Zen

Wall Street Zen upgraded shares of PicoCELA (NASDAQ:PCLA – Free Report) to a hold rating in a research note released on Saturday morning.

Separately, Weiss Ratings upgraded shares of PicoCELA from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, July 20th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock presently has an average rating of “Sell”.

Get PicoCELA alerts:

Get Our Latest Analysis on PicoCELA

PicoCELA Trading Up 4.2%

NASDAQ:PCLA opened at $5.41 on Friday. The firm’s fifty day moving average price is $5.51 and its 200 day moving average price is $4.44. PicoCELA has a 1-year low of $1.35 and a 1-year high of $19.50.

Institutional Investors Weigh In On PicoCELA

An institutional investor recently bought a new stake in PicoCELA stock. Jane Street Group LLC purchased a new position in shares of PicoCELA Inc. (NASDAQ:PCLA – Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 172,132 shares of the company’s stock, valued at approximately $52,000. Jane Street Group LLC owned 18.92% of PicoCELA as of its most recent SEC filing.

About PicoCELA

(Get Free Report)

PicoCELA, Inc is a clinical-stage biotechnology company focused on the development of next-generation vaccines and immunotherapies based on its proprietary self-assembling protein nanoparticle platform. The company engineers functionalized, virus-like protein particles designed to present disease-relevant antigens in their native conformation, with the goal of eliciting potent B-cell and T-cell responses. PicoCELA’s platform enables the rapid design and production of vaccine candidates against infectious diseases as well as antigen-specific immunotherapies for certain cancers.

The company’s pipeline includes vaccine programs targeting SARS-CoV-2 and other respiratory pathogens, leveraging its nanoparticle scaffolds to display full-length viral spike proteins or other key antigens.

Further Reading

• Five stocks we like better than PicoCELA
• Telecom Earnings Reveal a Sector That Finally Looks Healthier
• Defense Earnings Show Readiness Now and Modernization Ahead
• Why Palantir Investors Aren’t Panicking While the Rest of AI Sells Off
• MarketBeat Week in Review – 07/20- 07/24

Receive News & Ratings for PicoCELA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PicoCELA and related companies with MarketBeat.com's FREE daily email newsletter.